intrahepatic%20cholestasis
INTRAHEPATIC CHOLESTASIS
Cholestasis is bile formation and/or bile flow impairment that manifests as fatigue, pruritus and jaundice.
It can be classified into intrahepatic or extrahepatic cholestasis.
Extrahepatic cholestasis develops from mechanical blockage in the duct system or hepatocellular defects.
Intrahepatic cholestasis may be due to functional defects hepatocellularly or from obstructive lesions of the intrahepatic biliary tract distal from the bile canaliculi.

Intrahepatic%20cholestasis Management

Follow Up

  • In patients with PSC, suspect cholangiocarcinoma if with weight loss, worsening cholestasis, elevated serum level of CA 19-9, and/or new or progressive stricture, especially with an enhancing mass lesion 
  • Follow-up in ICP patients should be long enough to ensure a normalization of LFTs, and it is reasonable to check LFTs at 6 weeks
    • If after 6 months there is no improvement, further specialist input will be required 
  • ICP should settle spontaneously following delivery
  • The outcome of drug-induced cholestasis after withdrawal of the drug is generally good and few patients who develop DILI show abnormal liver tests and persistent histological evidence of liver damage at follow-up
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 18 Nov 2020
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).